Company news

MetaVia Inc. news in 2026

MetaVia Inc.'s news releases, calls and decks from 2026, newest first.

View company

MetaVia Announces Statistically Significant 68% Reduction in Liver Fat from DA-1726 Phase 1 Part 3B Interim Data

November 5, 2026

MetaVia to Present Phase 1 Clinical Trial Data for DA-1726 in Oral Presentation at the Precision Liver Symposium 2026

October 28, 2026

MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical Officer

October 13, 2026

MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction

September 9, 2026

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

July 9, 2026

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

June 8, 2026

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

May 27, 2026

MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH

May 20, 2026

MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions

May 18, 2026

MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026

MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026

May 11, 2026

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

April 9, 2026

MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

March 25, 2026

MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

March 17, 2026

MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035

March 11, 2026

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

March 4, 2026

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

February 17, 2026

MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041

February 13, 2026

MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel

February 4, 2026

MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726…

January 21, 2026

MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option

January 16, 2026

MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

January 15, 2026

MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile

January 5, 2026

Decks in 2026